Cellares has raised $257 million in a Series D financing round as it advances plans to support clinical cell therapy production this year and offer commercial-scale manufacturing services in 2027. The San Francisco–based company last year became the first organization to receive the U.S. Food and Drug Administration’s advanced manufacturing technology (AMT) designation, a milestone that coincides with its efforts to scale automated cell therapy manufacturing.
The Series D round brings Cellares’ total capital raised to $612 million. The company previously secured $255 million in a Series C financing in 2023, following earlier private funding rounds. According to Endpoints News, Cellares is planning an initial public offering as early as the fourth quarter of 2027, aligning with its preparations to begin commercial-stage production in the same year.
Cellares has developed the Cell Shuttle platform, a closed and automated system designed to perform end-to-end cell therapy manufacturing within a compact unit. The company states that the platform integrates multiple stages of production into a single, contained system, with the aim of reducing process failures, labor requirements, and facility space needs. The platform is intended for the manufacture of CAR T therapies and other cell-based treatments.
The newly raised funds will be used to complete construction of manufacturing facilities in Japan and the Netherlands. These sites will join Cellares’ commercial-ready facility in Bridgewater, New Jersey, as well as its original factory in South San Francisco. Earlier this month, the company disclosed that it had signed a long-term lease for 105,000 square feet of laboratory and office space in Leiden, the Netherlands.
The life sciences facility is currently under development, with construction expected to be completed in the first quarter of 2026. Following construction, the site will be prepared for operations with the aim of supporting clinical production later this year and commercial-scale manufacturing services in 2027. The Leiden facility will also serve as Cellares’ European headquarters.
Cellares has emphasized the importance of regional manufacturing capacity for cell therapies, which are often personalized and time-sensitive. The Netherlands facility is intended to position the company to manufacture therapies for patients in Europe, supporting programs as they move through clinical development and into commercial use.
The Series D financing was co-led by Eclipse and BlackRock. Additional new investors include T. Rowe Price, Baillie Gifford, Gates Frontier, Duquesne Family Office, Intuitive Ventures, and EDBI. Existing investors DC Global Ventures, DFJ Growth, and Willett Advisors also participated in the round.
Cellares’ customers include Bristol Myers Squibb, which in 2024 entered into a worldwide CAR T capacity reservation and supply agreement with the company valued at up to $380 million in upfront and milestone payments. The agreement positions Cellares to manufacture CAR T cell therapies for Bristol Myers Squibb in the United States, the European Union, and Japan. Bristol Myers Squibb markets the CAR T cancer treatments Abecma and Breyanzi and also operates its own cell therapy manufacturing facilities.
In addition to its work with Bristol Myers Squibb, Cellares has partnered with Cabaletta Bio. Through this collaboration, Cellares expects to manufacture the first good manufacturing practice cell therapy product for clinical use on the Cell Shuttle platform. The FDA recently cleared an amendment to Cabaletta’s clinical trial authorization, enabling the biotech to begin infusing patients with CAR T cell therapies produced using the Cell Shuttle system in the first half of 2026.
Andrew Farris, managing director at BlackRock, said, “Cellares is building the high-tech, industrial backbone required for cell therapy to scale globally.”
Cellares Secures Major Series D Funding for Global Expansion
Cellares has closed a $257 million Series D financing round co-led by BlackRock and Eclipse to support Cellares’ global expansion of automated cell therapy manufacturing facilities. Cellares’ new funding brings the company’s total capital raised to around $612 million, affirming Cellares’ position as a leading integrated development and manufacturing organization (IDMO) in the cell therapy industry.
Cellares Builds Smart Factories for High-Throughput Production
The Series D financing will enable Cellares to build and deploy automated “Smart Factory” facilities in key global hubs, including South San Francisco, Bridgewater (New Jersey), Leiden (the Netherlands), and Kashiwa City (Japan). Cellares’ smart factories are designed to industrialize cell therapy manufacturing with automated end-to-end systems like the Cell Shuttle™ and Cell Q™, helping Cellares deliver higher throughput, lower costs, and greater consistency than traditional manual processes.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
